Can the optic nerve be repaired?

Alastair Wilkins; Neil Scolding

doi:10.1016/S1474-4422(16)30402-1

Can the optic nerve be repaired?

Alastair Wilkins, Neil Scolding

Research output: Contribution to journal › Comment/debate (Academic Journal) › peer-review

411 Downloads (Pure)

Abstract

40 years ago, Bill Blakemore showed that transplanted Schwann cells repaired spinal cord myelin following experimental demyelination.1 The research, presciently funded by the UK Multiple Sclerosis Society, opened the field of cell therapy for multiple sclerosis. Ironically, although this field has developed successfully in various directions, not a single trial of myelinating cell transplantation in multiple sclerosis has been reported in the intervening four decades. Nonetheless, there is a direct link spanning Blakemore's pioneering work and the optic neuritis monoclonal antibody trial RENEW now reported in The Lancet Neurology.

Original language	English
Pages (from-to)	172-173
Number of pages	2
Journal	Lancet Neurology
Volume	16
Issue number	3
Early online date	15 Feb 2017
DOIs	https://doi.org/10.1016/S1474-4422(16)30402-1
Publication status	Published - Mar 2017

Access to Document

10.1016/S1474-4422(16)30402-1

Full-text PDF (accepted author manuscript)
This is the author accepted manuscript (AAM). The final published version (version of record) is available online via http://www.sciencedirect.com/science/article/pii/S1474442216304021. Please refer to any applicable terms of use of the publisher.
Accepted author manuscript, 203 KBLicence: CC BY-NC-ND

Handle.net

Persistent link

Cite this

@article{0ca29967e8ed4f25a6c8f103373e52fb,

title = "Can the optic nerve be repaired?",

abstract = "40 years ago, Bill Blakemore showed that transplanted Schwann cells repaired spinal cord myelin following experimental demyelination.1 The research, presciently funded by the UK Multiple Sclerosis Society, opened the field of cell therapy for multiple sclerosis. Ironically, although this field has developed successfully in various directions, not a single trial of myelinating cell transplantation in multiple sclerosis has been reported in the intervening four decades. Nonetheless, there is a direct link spanning Blakemore's pioneering work and the optic neuritis monoclonal antibody trial RENEW now reported in The Lancet Neurology.",

author = "Alastair Wilkins and Neil Scolding",

year = "2017",

month = mar,

doi = "10.1016/S1474-4422(16)30402-1",

language = "English",

volume = "16",

pages = "172--173",

journal = "Lancet Neurology",

issn = "1474-4422",